Economic and clinical benefits of ustekinumab in the treatment of moderate to severe psoriasis in Greece
نویسندگان
چکیده
Economic and clinical benefits of ustekinumab in the treatment of moderate to severe psoriasis in Greece Ioannis Bassukas, Georgios Chaidemenos, Andreas Katsampas, Marita Kosmadaki, Hara Kousoulakou, Athanasios Petridis, Brad Schenkel, Dimitrios Sotiriadis, Theofanis Spiliopoulos, Panagiotis Stavropoulos, Evgenia Toumpi, Loukas Xaplanteris. 1 Department of Skin and Venereal Diseases, University of Ioannina 2 Department of Dermatology, Hospital for Skin and Venereal Diseases, Thessaloniki 3 Department of Dermatology, University of Athens, Hospital “A. Syggros” 4 Department of Dermatology, Medical School, Aristotle University of Thessaloniki 5 Department of Dermatology, University of Patras Department of Dermatology and Venereology, "Attikon" General University Hospital, Athens 7 Janssen Cilag Pharmaceutical SACI, Athens Greece 8 PRMA Consulting Ltd, Hampshire, United Kingdom 9 Johnson and Johnson Pharmaceutical Services, LLC, Horsham, PA; These authors contributed equally to this work. §Corresponding author
منابع مشابه
Budget impact analysis of ustekinumab in the management of moderate to severe psoriasis in Greece
BACKGROUND The purpose of this study was to estimate the annual and per-patient budget impact of the treatment of moderate to severe psoriasis in Greece before and after the introduction of ustekinumab. METHODS A budget impact model was constructed from a national health system perspective to depict the clinical and economic aspects of psoriasis treatment over 5 years. The model included drug...
متن کاملEconomic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis
Background The continuous use of biologic agents in the treatment of psoriasis has been reported to result in successful and sustained therapeutic effects and safety. However, some patients choose intermittent and repetitive treatment. Objective To determine the factors for selecting intermittent and repetitive ustekinumab treatment for the management of psoriasis. Methods From January 2011...
متن کاملPhase 3 Clinical Trials Support STELARA® (ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
متن کامل
Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
[This corrects the article on p. 73 in vol. 7, PMID: 25609988.].
متن کاملSerum vascular endothelial growth factor in Iranian patients with moderate-severe psoriasis before and after treatment: a PASI-75 response as a practical treatment goal
Background: Psoriasis is a chronic disease with multiple biochemical and vascular abnormalities. Several studies have evaluated circulating levels of vascular endothelial growth factor (VEGF) in psoriasis, but none of them evaluated it after reaching a PASI-75 response, as a practical treatment goal. The aim of this study was to evaluate serum levels of VEGF in moderate to severe psoriatic pati...
متن کامل